ArticleCancer nanotechnology2018
Important parameters for optimized metal nanoparticles-aided electromagnetic field (EMF) effect on cancer.
Article in Cancer nanotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA number of experimental research findings for the metal nanoparticles (NPs)-mediated EMF photothermal therapy of cancer cells show an intriguing trend of the NPs' size-dependent efficacy. This is a phenomenon we find to trend with the light absorption bandwidth behavior (full width at half maximum) of the NPs and the accompanying electric field enhancement. We find that the nanoparticle sizes that have been reported to produce the optimized effect on cancer cells are of minimum absorption bandwidth and optimized electric field magnitude. While the death of cancer cells under the NPs-aided EMF effect has in the past attracted varied interpretations, either as a thermal or non-thermal effect, photothermal effect has gained a wide acceptance due to the exhibited hyperthermia. However, the exhibited trend of the NPs' size-dependent efficacy is beginning to feature as a possible manifestation of other overlooked underlying or synergistic phenomenal conditions.
methodWe present a theoretical model and analysis which reveal that the contribution and efficacy of the metal NPs in the destruction of cancer depend partly but significantly on the accompanying electric field intensity enhancement factor and partly on their absorption cross-section.
resultsThis paper finds that, other than the expected hyperthermia, the metal NPs' sizes for the optimized therapy on cancer cells seem to fulfill other synergistic conditions which need to come to the fore. We find interplay between electric field and thermal effects as independent energy channels where balancing may be important for the optimized EMF effect, in the ratio of about 5:1. The required balancing depends on the absorption bandwidth and absorption cross-section of the NPs, the frequency of EMF used and the relative permittivity of the cancer cells. The NPs' size-dependent efficacy decreases away from the NPs' size of minimum absorption bandwidth, which is around 20 nm for Au NPs or other shapes of equivalent surface area-volume ratio. While the absorption wavelength peak for metal NPs would change with the change of shape, the responsible condition(s) for optimizing the efficacy remains relatively invariable.
conclusionFrom the modeling and the analysis of the NPs' size for optimizing the EMF therapy on cancer cells, the ratio of electric field enhancement by metal NPs to the associated thermal effect is a very important factor for efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.